FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Foley Todd				RF	2. Issuer Name and Ticker or Trading Symbol RHYTHM PHARMACEUTICALS, INC. [RYTM]								Relationship of Reporting (Check all applicable) X Director Officer (give title)				10% Owner		
(Last) (First) (Middle) C/O MPM ASSET MANAGEMENT 450 KENDALL STREET				05/	3. Date of Earliest Transaction (Month/Day/Year) 05/27/2020									below) ⁽⁽⁾		belov	n)`` ,	
(Street) CAMBRIDGE MA 02142				_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(St		Zip)																
		Table	I - Non-Deriv	ative	Secu	rities <i>F</i>	\cqu	uired,	Dis	sposed o	f, or E	Benefici	ally (Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/			/ear) i	Execution Date,		3. Transaction Code (Instr. 8)		า D	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			Beneficia		es ally Following		Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Co	de V	А	mount	(A) or (D)	Price	Tra	insact	action(s) 3 and 4)		-4,	(111511.4)	
Common Stock 05/27/2020				20)		S((1)		10,148 ⁽²⁾	D	\$20.13(3)		2,090,299		I		See Footnote ⁽⁴⁾	
Common Stock 05/28/202			20	0		S((1)		19,152 ⁽⁵⁾	D	\$20.19	(6)	2,071,147		I		See Footnote ⁽⁷⁾		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed erivative Conversion Date Execution Date, Trans (Month/Day/Year) if any Code			5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ber ive ies ed	6. Date Ex Expiration (Month/Da		cisable and	7. Titl Amou Secur Under Deriva	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		ce of ative ity 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownersh Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
				Code	e V	(A) (Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares							

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. The shares were sold as follows: 9,768 by MPM BioVentures V, L.P. ("BV V") and 380 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. Ansbert Gadicke, Luke Evnin and Todd Foley are the members of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- 3. The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$20.00 to \$20.24. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 4. Shares are held as follows: 2,012,131 by BV V and 78,168 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- 5. Shares were sold as follows: 18,436 by BV V and 716 by AM BV5.
- 6. The price in Column 4 is a weighted average sale price. The prices actually received ranged from \$20.00 to \$20.35. The Reporting Person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- 7. Shares are held as follows: 1,993,695 by BV V and 77,452 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Remarks:

/s/ Todd Folev

05/28/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.